nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—chronic obstructive pulmonary disease	0.295	0.509	CbGaD
Dexmedetomidine—CYP1A2—chronic obstructive pulmonary disease	0.285	0.491	CbGaD
Dexmedetomidine—CYP2E1—Aminophylline—chronic obstructive pulmonary disease	0.0671	0.313	CbGbCtD
Dexmedetomidine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0388	0.181	CbGbCtD
Dexmedetomidine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0376	0.175	CbGbCtD
Dexmedetomidine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0376	0.175	CbGbCtD
Dexmedetomidine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0335	0.156	CbGbCtD
Dexmedetomidine—Bronchospasm—Formoterol—chronic obstructive pulmonary disease	0.00049	0.00344	CcSEcCtD
Dexmedetomidine—Bronchospasm—Arformoterol—chronic obstructive pulmonary disease	0.00049	0.00344	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.000486	0.00342	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000482	0.00338	CcSEcCtD
Dexmedetomidine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000477	0.00335	CcSEcCtD
Dexmedetomidine—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.000476	0.00334	CcSEcCtD
Dexmedetomidine—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.000473	0.00332	CcSEcCtD
Dexmedetomidine—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.000468	0.00329	CcSEcCtD
Dexmedetomidine—Bronchospasm—Salbutamol—chronic obstructive pulmonary disease	0.000462	0.00325	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00046	0.00323	CcSEcCtD
Dexmedetomidine—Sweating increased—Salbutamol—chronic obstructive pulmonary disease	0.000458	0.00322	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.000456	0.0032	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000449	0.00315	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000449	0.00315	CcSEcCtD
Dexmedetomidine—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.000448	0.00315	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000445	0.00313	CcSEcCtD
Dexmedetomidine—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.000441	0.0031	CcSEcCtD
Dexmedetomidine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000441	0.0031	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Arformoterol—chronic obstructive pulmonary disease	0.000438	0.00307	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Formoterol—chronic obstructive pulmonary disease	0.000438	0.00307	CcSEcCtD
Dexmedetomidine—Pneumonia—Montelukast—chronic obstructive pulmonary disease	0.000437	0.00307	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.00306	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.000435	0.00306	CcSEcCtD
Dexmedetomidine—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.000433	0.00304	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000431	0.00303	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000431	0.00303	CcSEcCtD
Dexmedetomidine—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00043	0.00302	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Montelukast—chronic obstructive pulmonary disease	0.000426	0.00299	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000424	0.00298	CcSEcCtD
Dexmedetomidine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000419	0.00294	CcSEcCtD
Dexmedetomidine—Neuritis—Prednisone—chronic obstructive pulmonary disease	0.000418	0.00294	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00289	CcSEcCtD
Dexmedetomidine—Fluid retention—Prednisolone—chronic obstructive pulmonary disease	0.000408	0.00287	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000407	0.00286	CcSEcCtD
Dexmedetomidine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000395	0.00277	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00276	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00276	CcSEcCtD
Dexmedetomidine—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00273	CcSEcCtD
Dexmedetomidine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000387	0.00272	CcSEcCtD
Dexmedetomidine—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.000384	0.0027	CcSEcCtD
Dexmedetomidine—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.000384	0.0027	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Prednisolone—chronic obstructive pulmonary disease	0.000382	0.00269	CcSEcCtD
Dexmedetomidine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000382	0.00268	CcSEcCtD
Dexmedetomidine—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.000378	0.00266	CcSEcCtD
Dexmedetomidine—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.000376	0.00264	CcSEcCtD
Dexmedetomidine—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000371	0.00261	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.00037	0.0026	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.00037	0.0026	CcSEcCtD
Dexmedetomidine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00037	0.0026	CcSEcCtD
Dexmedetomidine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000369	0.00259	CcSEcCtD
Dexmedetomidine—Delirium—Prednisone—chronic obstructive pulmonary disease	0.000363	0.00255	CcSEcCtD
Dexmedetomidine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000363	0.00255	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000362	0.00254	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000359	0.00252	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000359	0.00252	CcSEcCtD
Dexmedetomidine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000358	0.00251	CcSEcCtD
Dexmedetomidine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.000356	0.0025	CcSEcCtD
Dexmedetomidine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.0025	CcSEcCtD
Dexmedetomidine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000355	0.00249	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000352	0.00247	CcSEcCtD
Dexmedetomidine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000352	0.00247	CcSEcCtD
Dexmedetomidine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000351	0.00247	CcSEcCtD
Dexmedetomidine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000349	0.00245	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000349	0.00245	CcSEcCtD
Dexmedetomidine—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00245	CcSEcCtD
Dexmedetomidine—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00245	CcSEcCtD
Dexmedetomidine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000348	0.00245	CcSEcCtD
Dexmedetomidine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000348	0.00244	CcSEcCtD
Dexmedetomidine—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000347	0.00244	CcSEcCtD
Dexmedetomidine—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000347	0.00244	CcSEcCtD
Dexmedetomidine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000342	0.0024	CcSEcCtD
Dexmedetomidine—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000342	0.0024	CcSEcCtD
Dexmedetomidine—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.0024	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000339	0.00238	CcSEcCtD
Dexmedetomidine—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.00237	CcSEcCtD
Dexmedetomidine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00236	CcSEcCtD
Dexmedetomidine—Leukocytosis—Prednisone—chronic obstructive pulmonary disease	0.000332	0.00233	CcSEcCtD
Dexmedetomidine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000331	0.00233	CcSEcCtD
Dexmedetomidine—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00033	0.00232	CcSEcCtD
Dexmedetomidine—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.0023	CcSEcCtD
Dexmedetomidine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000319	0.00224	CcSEcCtD
Dexmedetomidine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000319	0.00224	CcSEcCtD
Dexmedetomidine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000312	0.00219	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000304	0.00214	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000303	0.00213	CcSEcCtD
Dexmedetomidine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000301	0.00211	CcSEcCtD
Dexmedetomidine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.0003	0.00211	CcSEcCtD
Dexmedetomidine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.0021	CcSEcCtD
Dexmedetomidine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000299	0.0021	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000297	0.00208	CcSEcCtD
Dexmedetomidine—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.000296	0.00208	CcSEcCtD
Dexmedetomidine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000294	0.00207	CcSEcCtD
Dexmedetomidine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00207	CcSEcCtD
Dexmedetomidine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00207	CcSEcCtD
Dexmedetomidine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000294	0.00207	CcSEcCtD
Dexmedetomidine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000294	0.00207	CcSEcCtD
Dexmedetomidine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000289	0.00203	CcSEcCtD
Dexmedetomidine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000289	0.00203	CcSEcCtD
Dexmedetomidine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000288	0.00202	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000287	0.00201	CcSEcCtD
Dexmedetomidine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.00199	CcSEcCtD
Dexmedetomidine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.00198	CcSEcCtD
Dexmedetomidine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000281	0.00198	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000278	0.00195	CcSEcCtD
Dexmedetomidine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000278	0.00195	CcSEcCtD
Dexmedetomidine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000277	0.00195	CcSEcCtD
Dexmedetomidine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00194	CcSEcCtD
Dexmedetomidine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00194	CcSEcCtD
Dexmedetomidine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00193	CcSEcCtD
Dexmedetomidine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00192	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00191	CcSEcCtD
Dexmedetomidine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000271	0.00191	CcSEcCtD
Dexmedetomidine—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000271	0.0019	CcSEcCtD
Dexmedetomidine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000266	0.00187	CcSEcCtD
Dexmedetomidine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000265	0.00186	CcSEcCtD
Dexmedetomidine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.00186	CcSEcCtD
Dexmedetomidine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000263	0.00184	CcSEcCtD
Dexmedetomidine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00183	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00182	CcSEcCtD
Dexmedetomidine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000254	0.00179	CcSEcCtD
Dexmedetomidine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000252	0.00177	CcSEcCtD
Dexmedetomidine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000252	0.00177	CcSEcCtD
Dexmedetomidine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000252	0.00177	CcSEcCtD
Dexmedetomidine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000252	0.00177	CcSEcCtD
Dexmedetomidine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00175	CcSEcCtD
Dexmedetomidine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000246	0.00173	CcSEcCtD
Dexmedetomidine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000246	0.00173	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000244	0.00172	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000244	0.00172	CcSEcCtD
Dexmedetomidine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000242	0.0017	CcSEcCtD
Dexmedetomidine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000242	0.0017	CcSEcCtD
Dexmedetomidine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000242	0.0017	CcSEcCtD
Dexmedetomidine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000242	0.0017	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000239	0.00168	CcSEcCtD
Dexmedetomidine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000238	0.00167	CcSEcCtD
Dexmedetomidine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000238	0.00167	CcSEcCtD
Dexmedetomidine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000237	0.00167	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000237	0.00166	CcSEcCtD
Dexmedetomidine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000236	0.00166	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.00166	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.00166	CcSEcCtD
Dexmedetomidine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000235	0.00165	CcSEcCtD
Dexmedetomidine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000234	0.00165	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000233	0.00164	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.00164	CcSEcCtD
Dexmedetomidine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000233	0.00164	CcSEcCtD
Dexmedetomidine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000232	0.00163	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.00163	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000231	0.00163	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000231	0.00162	CcSEcCtD
Dexmedetomidine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00161	CcSEcCtD
Dexmedetomidine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00161	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000227	0.00159	CcSEcCtD
Dexmedetomidine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00157	CcSEcCtD
Dexmedetomidine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00157	CcSEcCtD
Dexmedetomidine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00157	CcSEcCtD
Dexmedetomidine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00157	CcSEcCtD
Dexmedetomidine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000223	0.00157	CcSEcCtD
Dexmedetomidine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00155	CcSEcCtD
Dexmedetomidine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00155	CcSEcCtD
Dexmedetomidine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000221	0.00155	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00155	CcSEcCtD
Dexmedetomidine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00022	0.00154	CcSEcCtD
Dexmedetomidine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00022	0.00154	CcSEcCtD
Dexmedetomidine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00154	CcSEcCtD
Dexmedetomidine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00154	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00154	CcSEcCtD
Dexmedetomidine—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.00152	CcSEcCtD
Dexmedetomidine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000216	0.00152	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000216	0.00151	CcSEcCtD
Dexmedetomidine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00148	CcSEcCtD
Dexmedetomidine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00148	CcSEcCtD
Dexmedetomidine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.00146	CcSEcCtD
Dexmedetomidine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.00146	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000206	0.00145	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.0002	0.0014	CcSEcCtD
Dexmedetomidine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000197	0.00139	CcSEcCtD
Dexmedetomidine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.00136	CcSEcCtD
Dexmedetomidine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000194	0.00136	CcSEcCtD
Dexmedetomidine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000193	0.00135	CcSEcCtD
Dexmedetomidine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000191	0.00134	CcSEcCtD
Dexmedetomidine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00019	0.00133	CcSEcCtD
Dexmedetomidine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00131	CcSEcCtD
Dexmedetomidine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00131	CcSEcCtD
Dexmedetomidine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000183	0.00129	CcSEcCtD
Dexmedetomidine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00128	CcSEcCtD
Dexmedetomidine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00126	CcSEcCtD
Dexmedetomidine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00126	CcSEcCtD
Dexmedetomidine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00125	CcSEcCtD
Dexmedetomidine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00125	CcSEcCtD
Dexmedetomidine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00125	CcSEcCtD
Dexmedetomidine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00125	CcSEcCtD
Dexmedetomidine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000177	0.00125	CcSEcCtD
Dexmedetomidine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.00125	CcSEcCtD
Dexmedetomidine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00124	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000177	0.00124	CcSEcCtD
Dexmedetomidine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00124	CcSEcCtD
Dexmedetomidine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00123	CcSEcCtD
Dexmedetomidine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00123	CcSEcCtD
Dexmedetomidine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000174	0.00122	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000172	0.00121	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000171	0.0012	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000171	0.0012	CcSEcCtD
Dexmedetomidine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00119	CcSEcCtD
Dexmedetomidine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00118	CcSEcCtD
Dexmedetomidine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00118	CcSEcCtD
Dexmedetomidine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00118	CcSEcCtD
Dexmedetomidine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00118	CcSEcCtD
Dexmedetomidine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00118	CcSEcCtD
Dexmedetomidine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00116	CcSEcCtD
Dexmedetomidine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.00114	CcSEcCtD
Dexmedetomidine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00114	CcSEcCtD
Dexmedetomidine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.00016	0.00112	CcSEcCtD
Dexmedetomidine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00112	CcSEcCtD
Dexmedetomidine—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000158	0.00111	CcSEcCtD
Dexmedetomidine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000157	0.0011	CcSEcCtD
Dexmedetomidine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000156	0.0011	CcSEcCtD
Dexmedetomidine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.00105	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.00104	CcSEcCtD
Dexmedetomidine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000999	CcSEcCtD
Dexmedetomidine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000984	CcSEcCtD
Dexmedetomidine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000965	CcSEcCtD
Dexmedetomidine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000959	CcSEcCtD
Dexmedetomidine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000921	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000887	CcSEcCtD
Dexmedetomidine—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000886	CcSEcCtD
Dexmedetomidine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000881	CcSEcCtD
Dexmedetomidine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000831	CcSEcCtD
Dexmedetomidine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000828	CcSEcCtD
Dexmedetomidine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000814	CcSEcCtD
Dexmedetomidine—Infection—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000777	CcSEcCtD
Dexmedetomidine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000764	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000757	CcSEcCtD
Dexmedetomidine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000712	CcSEcCtD
Dexmedetomidine—Rash—Prednisolone—chronic obstructive pulmonary disease	9.67e-05	0.000679	CcSEcCtD
Dexmedetomidine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.66e-05	0.000678	CcSEcCtD
Dexmedetomidine—Headache—Prednisolone—chronic obstructive pulmonary disease	9.6e-05	0.000675	CcSEcCtD
Dexmedetomidine—Constipation—Prednisone—chronic obstructive pulmonary disease	9.53e-05	0.000669	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	9.18e-05	0.000645	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	9.11e-05	0.00064	CcSEcCtD
Dexmedetomidine—Nausea—Prednisolone—chronic obstructive pulmonary disease	9.11e-05	0.00064	CcSEcCtD
Dexmedetomidine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.81e-05	0.000619	CcSEcCtD
Dexmedetomidine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.81e-05	0.000619	CcSEcCtD
Dexmedetomidine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.000535	CcSEcCtD
Dexmedetomidine—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.37e-05	0.000517	CcSEcCtD
Dexmedetomidine—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.08e-05	0.000498	CcSEcCtD
Dexmedetomidine—Rash—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000493	CcSEcCtD
Dexmedetomidine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000493	CcSEcCtD
Dexmedetomidine—Headache—Prednisone—chronic obstructive pulmonary disease	6.98e-05	0.00049	CcSEcCtD
Dexmedetomidine—Nausea—Prednisone—chronic obstructive pulmonary disease	6.62e-05	0.000465	CcSEcCtD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.08e-05	0.000491	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GC—chronic obstructive pulmonary disease	3.07e-05	0.000491	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.05e-05	0.000487	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.05e-05	0.000487	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.04e-05	0.000486	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.03e-05	0.000484	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.01e-05	0.000482	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.01e-05	0.000481	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	2.97e-05	0.000474	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.96e-05	0.000473	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.92e-05	0.000467	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.89e-05	0.000462	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—NOS2—chronic obstructive pulmonary disease	2.87e-05	0.000459	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.87e-05	0.000459	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.86e-05	0.000456	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.85e-05	0.000455	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.84e-05	0.000454	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.8e-05	0.000447	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.72e-05	0.000435	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.72e-05	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.71e-05	0.000433	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.68e-05	0.000429	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.67e-05	0.000426	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.64e-05	0.000422	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	2.62e-05	0.000419	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.61e-05	0.000417	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.59e-05	0.000414	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	2.59e-05	0.000414	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—ALB—chronic obstructive pulmonary disease	2.59e-05	0.000413	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.58e-05	0.000412	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.57e-05	0.00041	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	2.54e-05	0.000406	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.49e-05	0.000397	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.47e-05	0.000395	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.46e-05	0.000392	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.45e-05	0.000392	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.45e-05	0.000391	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.44e-05	0.000389	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.42e-05	0.000387	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—ALB—chronic obstructive pulmonary disease	2.42e-05	0.000386	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	2.41e-05	0.000385	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.4e-05	0.000383	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.4e-05	0.000383	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.39e-05	0.000381	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.38e-05	0.00038	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.36e-05	0.000377	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GCLC—chronic obstructive pulmonary disease	2.36e-05	0.000377	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	2.34e-05	0.000373	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.33e-05	0.000372	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.31e-05	0.000369	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.31e-05	0.000369	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.31e-05	0.000369	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.29e-05	0.000366	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.29e-05	0.000366	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.26e-05	0.000361	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.26e-05	0.000361	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.26e-05	0.00036	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.25e-05	0.000359	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.25e-05	0.000359	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.18e-05	0.000348	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.18e-05	0.000348	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.17e-05	0.000346	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CTGF—chronic obstructive pulmonary disease	2.15e-05	0.000344	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.15e-05	0.000343	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.14e-05	0.000342	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.1e-05	0.000335	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.06e-05	0.00033	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.04e-05	0.000326	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.01e-05	0.000322	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.99e-05	0.000318	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.98e-05	0.000317	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.98e-05	0.000316	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	1.97e-05	0.000314	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	1.96e-05	0.000314	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.96e-05	0.000313	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.95e-05	0.000311	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.94e-05	0.00031	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	1.92e-05	0.000306	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.9e-05	0.000304	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	1.88e-05	0.0003	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.87e-05	0.000299	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.86e-05	0.000298	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.86e-05	0.000298	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.85e-05	0.000295	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.82e-05	0.000291	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.8e-05	0.000287	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.78e-05	0.000285	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.78e-05	0.000284	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.77e-05	0.000282	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.76e-05	0.000281	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	1.75e-05	0.000279	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.71e-05	0.000273	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.7e-05	0.000272	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.68e-05	0.000268	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.68e-05	0.000268	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.67e-05	0.000267	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.67e-05	0.000266	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.66e-05	0.000265	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.65e-05	0.000264	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.65e-05	0.000264	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.64e-05	0.000261	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.63e-05	0.000261	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.61e-05	0.000257	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.61e-05	0.000257	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.56e-05	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.55e-05	0.000247	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.55e-05	0.000247	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.54e-05	0.000246	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.54e-05	0.000245	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.53e-05	0.000245	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.53e-05	0.000244	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.52e-05	0.000244	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.52e-05	0.000243	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.51e-05	0.000242	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.48e-05	0.000236	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.45e-05	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.44e-05	0.00023	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.44e-05	0.00023	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.42e-05	0.000226	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.4e-05	0.000223	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.39e-05	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.39e-05	0.000222	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.39e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.38e-05	0.00022	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.36e-05	0.000218	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.35e-05	0.000216	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—chronic obstructive pulmonary disease	1.35e-05	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.34e-05	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.33e-05	0.000213	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.33e-05	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.3e-05	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.29e-05	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.28e-05	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.27e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.27e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.26e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—chronic obstructive pulmonary disease	1.26e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.25e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.25e-05	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.24e-05	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.24e-05	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.23e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.23e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.22e-05	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.2e-05	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.18e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.17e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.17e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.17e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.16e-05	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.16e-05	0.000185	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.15e-05	0.000184	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.15e-05	0.000183	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.14e-05	0.000182	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.13e-05	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.13e-05	0.00018	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.12e-05	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.11e-05	0.000177	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.07e-05	0.000172	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.07e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.07e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.06e-05	0.000169	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.05e-05	0.000168	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.05e-05	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.05e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.04e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.03e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	1.02e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.02e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.86e-06	0.000158	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ALB—chronic obstructive pulmonary disease	9.8e-06	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.73e-06	0.000155	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.65e-06	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.56e-06	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.49e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NOS3—chronic obstructive pulmonary disease	9.37e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.29e-06	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.21e-06	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.14e-06	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.79e-06	0.00014	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.76e-06	0.00014	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.64e-06	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.6e-06	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.5e-06	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.46e-06	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.39e-06	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.24e-06	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.21e-06	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.08e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.05e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	7.96e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.84e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.84e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.71e-06	0.000123	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.63e-06	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	7.61e-06	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.45e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.44e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.42e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.32e-06	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—chronic obstructive pulmonary disease	7.31e-06	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.08e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NOS3—chronic obstructive pulmonary disease	6.99e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.99e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.95e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	6.89e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.84e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.82e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.73e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.69e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.67e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.61e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	6.59e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.5e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.46e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.36e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.29e-06	0.0001	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.19e-06	9.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.14e-06	9.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.04e-06	9.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.02e-06	9.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.65e-06	9.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.65e-06	9.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.56e-06	8.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.55e-06	8.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.44e-06	8.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.37e-06	8.58e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	5.19e-06	8.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.18e-06	8.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.11e-06	8.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.1e-06	8.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.08e-06	8.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.06e-06	8.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5e-06	7.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.96e-06	7.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.63e-06	7.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.59e-06	7.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.57e-06	7.3e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.39e-06	7.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.27e-06	6.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.21e-06	6.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.2e-06	6.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.2e-06	6.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.18e-06	6.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.13e-06	6.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.9e-06	6.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.84e-06	6.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.46e-06	5.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.17e-06	5.07e-05	CbGpPWpGaD
